[article] 
inJournal of Autism and Developmental Disorders > 50-2 (February 2020) . - p.676-682

Titre :	Buspirone for the Treatment of Generalized Anxiety Disorder in Williams Syndrome: A Case Series
Type de document :	Texte imprimé et/ou numérique
Auteurs :	Robyn P. THOM, Auteur ; Christopher J. KEARY, Auteur ; Jessica L. WAXLER, Auteur ; Barbara R. POBER, Auteur ; Christopher J MCDOUGLE, Auteur
Article en page(s) :	p.676-682
Langues :	Anglais (eng)
Mots-clés :	Anxiety  Buspirone  Williams syndrome
Index. décimale :	PER Périodiques
Résumé :	Co-morbid anxiety disorders, including generalized anxiety disorder (GAD), are highly prevalent among individuals with Williams syndrome (WS). However, reports of the pharmacologic treatment of only a limited number of previous anxiety disorders in WS have appeared in the literature. Here, we review the case histories of three adolescents/young adults with WS and the treatment course of co-morbid GAD with buspirone. Treatment with buspirone was well-tolerated and resulted in sustained response in all three cases. Common medical disorders in WS are highlighted with regards to safe and appropriate pharmacologic treatment of GAD. Buspirone's generally benign side effect profile is a major benefit of its use for treating GAD in individuals with WS.
En ligne :	http://dx.doi.org/10.1007/s10803-019-04301-9
Permalink :	https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=416

[article] Buspirone for the Treatment of Generalized Anxiety Disorder in Williams Syndrome: A Case Series [Texte imprimé et/ou numérique] / Robyn P. THOM, Auteur ; Christopher J. KEARY, Auteur ; Jessica L. WAXLER, Auteur ; Barbara R. POBER, Auteur ; Christopher J MCDOUGLE, Auteur . - p.676-682.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 50-2 (February 2020) . - p.676-682

Mots-clés :	Anxiety  Buspirone  Williams syndrome
Index. décimale :	PER Périodiques
Résumé :	Co-morbid anxiety disorders, including generalized anxiety disorder (GAD), are highly prevalent among individuals with Williams syndrome (WS). However, reports of the pharmacologic treatment of only a limited number of previous anxiety disorders in WS have appeared in the literature. Here, we review the case histories of three adolescents/young adults with WS and the treatment course of co-morbid GAD with buspirone. Treatment with buspirone was well-tolerated and resulted in sustained response in all three cases. Common medical disorders in WS are highlighted with regards to safe and appropriate pharmacologic treatment of GAD. Buspirone's generally benign side effect profile is a major benefit of its use for treating GAD in individuals with WS.
En ligne :	http://dx.doi.org/10.1007/s10803-019-04301-9
Permalink :	https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=416